Nestler, J
Manypeoplebegin noticing support for appetite control and metabolic balance within 12 weeks of consistentuse.*
R.et al (2019)
ISRCTN Registry, ResearchGate 2 Glucose control & metabolic markers in type 2 diabetes / pre-diabetes 14 g/day for 852 weeks 2024 dose-response meta-analysis of 36 RCTs (n=3 214) found clinically meaningful reductions in fasting glucose (9 mg/dL), HbA1c (0.32 %) and HOMA-IR (0.43)
This post-medication support helps you preserve habits, adjust to appetite changes, and avoid rebound weight gain
Tirzepatide follows the same pattern: Mounjaro: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg for type 2 diabetes Zepbound: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg for obesity The doses are identical